Skip to main content
Top
Published in: American Journal of Cardiovascular Drugs 4/2014

01-08-2014 | Original Research Article

Severe Left Ventricular Systolic Dysfunction is Independently Associated with High On-Clopidogrel Platelet Reactivity

Authors: Zuzana Motovska, Martina Ondrakova, Magdalena Doktorova, Petr Widimsky

Published in: American Journal of Cardiovascular Drugs | Issue 4/2014

Login to get access

Abstract

Objective

The purpose of the present study was to investigate the association between left ventricular systolic function and the response to clopidogrel.

Methods

The efficacy of clopidogrel was measured by the vasodilator-stimulated phosphoprotein phosphorylation 20 ± 4 h after 600 mg of clopidogrel. High on-clopidogrel platelet reactivity (HCPR) was defined as a platelet reactivity index (PRI) ≥50 %. The 30-day combined incidence of death, non-fatal acute coronary syndrome, re-percutaneous coronary intervention (PCI), stent thrombosis, and stroke was also investigated.

Results

The study group consisted of 519 patients undergoing PCI. The values (mean and 95 % confidence interval) of the PRI were as follows: 40.4 % (37.8–43.0) in patients with left ventricular ejection fraction (LVEF) >50 %, 42.4 % (39.3–45.6) in patients with LVEF 35–50 %, and 46.7 % (40.6–52.9) in patients with LVEF <35 % (p = 0.013). The proportions of patients with HCPR were 35.9 % in patients with LVEF ≥35 and 51.9 % in patients with LVEF <35 % (p = 0.022). After adjustment for variables that significantly influenced clopidogrel efficacy, LVEF <35 % was found to be independently associated with HCPR (p = 0.039). The 30-day combined clinical endpoint occurred in 18 % of patients with LVEF <35 % and in 7.3 % of patients with LVEF ≥35 % (p = 0.026). The 30-day incidence of all-cause mortality was 14 % in patients with LVEF <35 and 1.0 % in patients with LVEF ≥35 % (p < 0.001).

Conclusion

An LVEF <35 % was found to be independently associated with HCPR.
Literature
1.
go back to reference Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB, for the Framingham Heart Study, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068–72.PubMedCrossRef Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB, for the Framingham Heart Study, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068–72.PubMedCrossRef
2.
go back to reference McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, from ESC Committee for Practice Guidelines, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847.PubMedCrossRef McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, from ESC Committee for Practice Guidelines, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847.PubMedCrossRef
3.
go back to reference Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–220.PubMedCrossRef Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–220.PubMedCrossRef
5.
go back to reference Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001;104:1577–9.PubMedCrossRef Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001;104:1577–9.PubMedCrossRef
6.
go back to reference Emond M, Mock MB, Davis KB, Fisher LD, Holmes DR Jr, Chaitman BR, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation. 1994;90:2645–57.PubMedCrossRef Emond M, Mock MB, Davis KB, Fisher LD, Holmes DR Jr, Chaitman BR, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation. 1994;90:2645–57.PubMedCrossRef
7.
go back to reference Michalsen A, König G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 1998;80:437–41.PubMedCentralPubMed Michalsen A, König G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 1998;80:437–41.PubMedCentralPubMed
8.
go back to reference Khand AU, Gemmell I, Rankin AC, Cleland JG. Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges. Eur Heart J. 2001;22:153–64.PubMedCrossRef Khand AU, Gemmell I, Rankin AC, Cleland JG. Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges. Eur Heart J. 2001;22:153–64.PubMedCrossRef
9.
go back to reference Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010;31:2501–55.PubMedCrossRef Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guidelines on myocardial revascularization. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010;31:2501–55.PubMedCrossRef
10.
go back to reference Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574–651. doi:10.1161/CIR.0b013e31823ba622. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574–651. doi:10.​1161/​CIR.​0b013e31823ba622​.
11.
go back to reference McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.PubMedCrossRef McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.PubMedCrossRef
12.
go back to reference Sardi GL, Gaglia MA Jr, Maluenda G, Torguson R, Laynez-Carnicero A, Ben-Dor I, et al. Outcome of percutaneous coronary intervention utilizing drug-eluting stents in patients with reduced left ventricular ejection fraction. Am J Cardiol. 2012;109:344–51.PubMedCrossRef Sardi GL, Gaglia MA Jr, Maluenda G, Torguson R, Laynez-Carnicero A, Ben-Dor I, et al. Outcome of percutaneous coronary intervention utilizing drug-eluting stents in patients with reduced left ventricular ejection fraction. Am J Cardiol. 2012;109:344–51.PubMedCrossRef
13.
go back to reference Keelan PC, Johnston JM, Koru-Sengul T, Detre KM, Williams DO, Slater J, et al. Comparison of in-hospital and one-year outcomes in patients with left ventricular ejection fractions < or = 40%, 41% to 49%, and > or = 50% having percutaneous coronary revascularization. Am J Cardiol. 2003;91:1168–72.PubMedCrossRef Keelan PC, Johnston JM, Koru-Sengul T, Detre KM, Williams DO, Slater J, et al. Comparison of in-hospital and one-year outcomes in patients with left ventricular ejection fractions < or = 40%, 41% to 49%, and > or = 50% having percutaneous coronary revascularization. Am J Cardiol. 2003;91:1168–72.PubMedCrossRef
14.
go back to reference Petr R, Motovska Z, Marinov I, Bilkova D, Widimsky P. Resistance to clopidogrel assessed by VASP phosphorylation is a negative prognostic factor in patients undergoing elective PCI for stable coronary artery disease: analysis from laboratory substudy of PRAGUE 8 trial. J Am Coll Cardiol. 2010;55:A98.E926. doi:10.1016/S0735-1097(10)60927-8. Petr R, Motovska Z, Marinov I, Bilkova D, Widimsky P. Resistance to clopidogrel assessed by VASP phosphorylation is a negative prognostic factor in patients undergoing elective PCI for stable coronary artery disease: analysis from laboratory substudy of PRAGUE 8 trial. J Am Coll Cardiol. 2010;55:A98.E926. doi:10.​1016/​S0735-1097(10)60927-8.
15.
go back to reference Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA. 2011;306:1215–23.PubMedCrossRef Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA. 2011;306:1215–23.PubMedCrossRef
16.
go back to reference Motovska Z, Widimsky P, Petr R, Bilkova D, Marinov I, Simek S, et al. Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectivity—the laboratory substudy of the PRAGUE-8 study. Int J Cardiol. 2010;144:255–7.PubMedCrossRef Motovska Z, Widimsky P, Petr R, Bilkova D, Marinov I, Simek S, et al. Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectivity—the laboratory substudy of the PRAGUE-8 study. Int J Cardiol. 2010;144:255–7.PubMedCrossRef
17.
go back to reference Bellemain-Appaix A, Montalescot G, Silvain J, Barthélémy O, Beygui F, Collet JP, ALBION Investigators, et al. Slow response to clopidogrel predicts low response. J Am Coll Cardiol. 2010;55:815–22.PubMedCrossRef Bellemain-Appaix A, Montalescot G, Silvain J, Barthélémy O, Beygui F, Collet JP, ALBION Investigators, et al. Slow response to clopidogrel predicts low response. J Am Coll Cardiol. 2010;55:815–22.PubMedCrossRef
18.
go back to reference Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Working Group on High On-Treatment Platelet Reactivity, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919–33.PubMedCrossRef Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Working Group on High On-Treatment Platelet Reactivity, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919–33.PubMedCrossRef
19.
go back to reference Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Academic Research Consortium, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–51.PubMedCrossRef Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Academic Research Consortium, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–51.PubMedCrossRef
20.
go back to reference European Perspectives in Cardiology Centres of Excellence: the Cardiocentre Prague, Czech Republic. Circulation. 2008;118(Suppl):f13–18. European Perspectives in Cardiology Centres of Excellence: the Cardiocentre Prague, Czech Republic. Circulation. 2008;118(Suppl):f13–18.
21.
go back to reference Michelson AD. Methods for the measurement of platelet function. Am J Cardiol. 2009;103(3 Suppl):20A–6A.PubMedCrossRef Michelson AD. Methods for the measurement of platelet function. Am J Cardiol. 2009;103(3 Suppl):20A–6A.PubMedCrossRef
22.
go back to reference Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness. J Thromb Haemost. 2010;8:482–8.PubMedCrossRef Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness. J Thromb Haemost. 2010;8:482–8.PubMedCrossRef
23.
go back to reference Gachet C, Aleil B. Testing antiplatelet therapy. Eur Heart J Suppl. 2008;10:A28–34.CrossRef Gachet C, Aleil B. Testing antiplatelet therapy. Eur Heart J Suppl. 2008;10:A28–34.CrossRef
24.
go back to reference Michelson AD, Frelinger AL, Furman MI. Resistance to antiplatelet drugs. Eur Heart J Suppl. 2006;8(suppl G):G53–8.CrossRef Michelson AD, Frelinger AL, Furman MI. Resistance to antiplatelet drugs. Eur Heart J Suppl. 2006;8(suppl G):G53–8.CrossRef
25.
go back to reference Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006;27:2420–5.PubMedCrossRef Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006;27:2420–5.PubMedCrossRef
27.
go back to reference Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Riesmeyer J, Weerakkody G, et al. TRITON-TIMI 38 trial investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371:1353–63.PubMedCrossRef Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Riesmeyer J, Weerakkody G, et al. TRITON-TIMI 38 trial investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371:1353–63.PubMedCrossRef
28.
go back to reference Shaw RE, Anderson HV, Brindis RG, Krone RJ, Klein LW, McKay CR, et al. Development of a risk adjustment mortality model using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR) experience: 1998–2000. J Am Coll Cardiol. 2002;39:1104–12.PubMedCrossRef Shaw RE, Anderson HV, Brindis RG, Krone RJ, Klein LW, McKay CR, et al. Development of a risk adjustment mortality model using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR) experience: 1998–2000. J Am Coll Cardiol. 2002;39:1104–12.PubMedCrossRef
29.
go back to reference De Silva K, Webb I, Sicard P, Lockie T, Pattinson S, Redwood S, et al. Does left ventricular function continue to influence mortality following contemporary percutaneous coronary intervention? Coronary Artery Dis. 2012;23:155–61.CrossRef De Silva K, Webb I, Sicard P, Lockie T, Pattinson S, Redwood S, et al. Does left ventricular function continue to influence mortality following contemporary percutaneous coronary intervention? Coronary Artery Dis. 2012;23:155–61.CrossRef
30.
go back to reference Peterson ED, Dai D, DeLong ER, Brennan JM, Singh M, Rao SV, on behalf of the NCDR Registry Participants, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol. 2010;55:1923–32.PubMedCentralPubMedCrossRef Peterson ED, Dai D, DeLong ER, Brennan JM, Singh M, Rao SV, on behalf of the NCDR Registry Participants, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol. 2010;55:1923–32.PubMedCentralPubMedCrossRef
31.
go back to reference Tanaka S, Sakata R, Marui A, Furukawa Y, Kita T, Kimura T, CREDO-Kyoto Investigators. Predicting long-term mortality after first coronary revascularization: the Kyoto model. Circ J. 2012;76:328–34.PubMedCrossRef Tanaka S, Sakata R, Marui A, Furukawa Y, Kita T, Kimura T, CREDO-Kyoto Investigators. Predicting long-term mortality after first coronary revascularization: the Kyoto model. Circ J. 2012;76:328–34.PubMedCrossRef
32.
go back to reference de Mulder M, Gitt A, van Domburg R, Hochadel M, Seabra-Gomes R, Serruys PW, et al. EuroHeart score for the evaluation of in-hospital mortality in patients undergoing percutaneous coronary intervention. Eur Heart J. 2011;32:1398–408.PubMedCrossRef de Mulder M, Gitt A, van Domburg R, Hochadel M, Seabra-Gomes R, Serruys PW, et al. EuroHeart score for the evaluation of in-hospital mortality in patients undergoing percutaneous coronary intervention. Eur Heart J. 2011;32:1398–408.PubMedCrossRef
33.
go back to reference Moussa I, Di Mario C, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol. 1997;29:6–12.PubMedCrossRef Moussa I, Di Mario C, Reimers B, Akiyama T, Tobis J, Colombo A. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol. 1997;29:6–12.PubMedCrossRef
34.
go back to reference Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–30.PubMedCrossRef Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–30.PubMedCrossRef
35.
go back to reference van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53:1399–409.PubMedCrossRef van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53:1399–409.PubMedCrossRef
36.
go back to reference Mehta J, Mehta P. Platelet function studies in heart disease. VI. Enhanced platelet aggregate formation activity in congestive heart failure: inhibition by sodium nitroprusside. Circulation. 1979;60:497–503.PubMedCrossRef Mehta J, Mehta P. Platelet function studies in heart disease. VI. Enhanced platelet aggregate formation activity in congestive heart failure: inhibition by sodium nitroprusside. Circulation. 1979;60:497–503.PubMedCrossRef
38.
go back to reference Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003;31:53–9.PubMedCrossRef Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003;31:53–9.PubMedCrossRef
39.
go back to reference Sica DA. Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics. Congest Heart Fail. 2003;9:287–92.PubMedCrossRef Sica DA. Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics. Congest Heart Fail. 2003;9:287–92.PubMedCrossRef
40.
go back to reference Sokol SI, Cheng A, Frishman WH, Kaza CS. Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure. J Clin Pharmacol. 2000;40:11–30.PubMedCrossRef Sokol SI, Cheng A, Frishman WH, Kaza CS. Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure. J Clin Pharmacol. 2000;40:11–30.PubMedCrossRef
41.
go back to reference Fradette C, Du Souich P. Effect of hypoxia on cytochrome P450 activity and expression. Curr Drug Metab. 2004;5:257–71.PubMedCrossRef Fradette C, Du Souich P. Effect of hypoxia on cytochrome P450 activity and expression. Curr Drug Metab. 2004;5:257–71.PubMedCrossRef
Metadata
Title
Severe Left Ventricular Systolic Dysfunction is Independently Associated with High On-Clopidogrel Platelet Reactivity
Authors
Zuzana Motovska
Martina Ondrakova
Magdalena Doktorova
Petr Widimsky
Publication date
01-08-2014
Publisher
Springer International Publishing
Published in
American Journal of Cardiovascular Drugs / Issue 4/2014
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI
https://doi.org/10.1007/s40256-014-0074-3

Other articles of this Issue 4/2014

American Journal of Cardiovascular Drugs 4/2014 Go to the issue